# Alaunos Therapeutics, Inc. (TCRT) · Edgar & Edgarette company card

> Alaunos Therapeutics (TCRT) saw revenue fall 50.0% in FY2025 to $0 million, operating margin -84500% against a -3.8% median for pharmaceutical preparations, equity 72.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1107421 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/TCRT) · [JSON](https://www.pops4.com/boards/company/TCRT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $5,000 |
| Revenue growth, 1 year | -50.0% |
| Revenue growth per year | -66.5% |
| Operating margin | -84500.0% (prior year -48120.0%) |
| Net margin | -83520.0% |
| Operating cash flow | −$3M |
| Capital spending | $98,000 |
| Free cash flow | −$3M |
| Cash | $1M |
| Long-term debt | — |
| Total assets | $3M |
| Total equity | $2M |
| Equity ÷ assets | 72.6% |
| Return on equity | -194.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -1020.47 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$2.9M in FY2025); operating loss: a margin of -84500.0% in FY2025; revenue is hard to predict: its 80% range is ±79%

## Edgarette's reading

Exposure: revenue $5K (FY2025). Experience: revenue down 50.0% on the year, down 66.5% a year over 4 years; operating margin -84500.0%, down from -48120.0%. Soundness: equity 72.6% of assets, return on equity -194.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1K and $5K next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $0K to $5K. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -84500.0% against a -3.8% median; growth -50.0% against 13.7%.

Range logged 2026-09-24, receipt abfb50718456afad, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 3, latest 2026-10-21 ([filing](https://www.sec.gov/Archives/edgar/data/1107421/000119312526427890/0001193125-26-427890-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-10-13 ([filing](https://www.sec.gov/Archives/edgar/data/1107421/000119312526419829/0001193125-26-419829-index.htm))

## Recent filings

- 8-K · filed 2026-10-23 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1107421/000119312526430507/0001193125-26-430507-index.htm)
- 8-K · filed 2026-10-21 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1107421/000119312526427890/0001193125-26-427890-index.htm)
- 8-K · filed 2026-10-13 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1107421/000119312526419829/0001193125-26-419829-index.htm)
- 8-K · filed 2026-10-09 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1107421/000119312526419154/0001193125-26-419154-index.htm)
- 8-K · filed 2026-09-22 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1107421/000119312526397996/0001193125-26-397996-index.htm)
- 8-K · filed 2026-09-17 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year · [filing](https://www.sec.gov/Archives/edgar/data/1107421/000119312526393462/0001193125-26-393462-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001107421.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1107421

## Cite

POPS4, Edgar & Edgarette: Alaunos Therapeutics, Inc. (TCRT) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/TCRT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.